The Short Bowel Syndrome Market is estimated to be valued at US$ 188.9 Bn in 2023 and is expected to exhibit a CAGR of 11.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Short bowel syndrome is a malabsorptive condition that occurs when the small intestine is partially or completely surgically removed thus significantly reducing the ability to digest and absorb nutrients from food. The main symptoms include diarrhea, dehydration, weight loss and malnutrition. Currently, treatment options include medication, nutrition therapy, injectable nutrition and supplements to improve intestinal functions and absorption of nutrients.
Short bowel syndrome market is expected to witness significant growth owing to the high cost of immunotherapy treatment and side effects of immunotherapy drugs. The cost of immunotherapy drugs to treat short bowel syndrome is substantially high which limits accessibility. For instance, teduglutide which is the only approved drug to treat short bowel syndrome costs around $132,000 annually in the US. Further, immunotherapy drugs used to treat short bowel syndrome are associated with side effects such as abdominal pain, distension, flatulence and fatigue which may hamper adoption. Additionally, lack of stringent regulatory guidelines for combination drug therapies in some regions remains a major challenge. However, ongoing research on promising pipeline drugs and nutraceuticals is estimated to provide new opportunities for market growth over the forecast period.
Strength: Short bowel syndrome market is witnessing high growth owing to increasing incidence of diseases requiring extensive bowel resection surgeries. Many pharmaceutical companies are focusing on development of novel drugs for short bowel syndrome treatment. Availability of reimbursement policies for short bowel syndrome treatment in developed countries.
Weakness: High cost of immunotherapy treatment. Side effects of immunotherapy drugs limits their adoption. Poor economical conditions in underdeveloped regions restrict market growth.
Opportunity: Favorable government support and initiatives to increase awareness. Emerging economies presents lucrative opportunities for market players due to growing healthcare expenditures. Collaboration between research institutes and pharmaceutical industries will foster innovation.
Threats: Stiff competition among existing market players hampers pricing flexibility. Stringent regulatory approvals delays product launches.
The Global Short Bowel Syndrome Market Growth is expected to witness high growth, exhibiting CAGR of 11.5% over the forecast period, due to increasing incidence of cancer, inflammatory bowel disease, and other conditions requiring extensive bowel resection surgeries.
North America dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to growing geriatric population suffering from intestinal conditions, availability of advanced treatment facilities, and favorable reimbursement policies. Asia Pacific exhibits the fastest growth owing to improving healthcare infrastructure and increasing healthcare spending in countries such as India and China.
Key players operating in the short bowel syndrome market are Ticarcillin, Merck & Co, Johnson & Johnson, B. Braun Melsungen, and 3M Company. These players are focused on new product launches and collaboration with regional players to strengthen their geographic presence.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it